8-K: DT Cloud Secures Funding, Faces Nasdaq Delisting Threat

DT Cloud Acquisition Corporation entered a private placement for its business combination with Maius Pharmaceutical, while simultaneously receiving a Nasdaq deficiency notice for low market value of publicly held shares.

Summary

• DT Cloud Acquisition Corporation (SPAC) entered into a Subscription Agreement on September 29, 2025, with Maius Pharmaceutical Co., Ltd. (Company), Maius Pharmaceutical Group Co., Ltd. (Pubco), and an investor.
• The investor agreed to subscribe for and purchase 15,000 ordinary shares of Pubco at a price of $10.00 per share in a private placement, totaling $150,000.
• This private placement is a financing effort related to the previously announced business combination, which involves the merger of SPAC and Maius into Pubco.
• On September 25, 2025, DT Cloud Acquisition Corporation received a deficiency letter from the Nasdaq Listing Qualifications Department.
• The notice indicated that the company's Market Value of Publicly Held Shares (MVPHS) had been below the minimum $15 million requirement for continued listing on the Nasdaq Global Market for 30 consecutive business days.
• The company has 180 calendar days, until March 24, 2026, to regain compliance with the Nasdaq MVPHS requirement.

Sentiment

Score: 4

Explanation: The private placement is a positive step towards financing the business combination, but the Nasdaq deficiency notice introduces significant uncertainty and risk regarding the company's continued listing, overshadowing the financing news.

Positives

• Secured a private placement of 15,000 ordinary shares at $10.00 per share, raising $150,000, to support the business combination.
• The business combination with Maius Pharmaceutical Co., Ltd. and Maius Pharmaceutical Group Co., Ltd. is progressing, with the private placement contingent on its consummation.

Negatives

• Received a Nasdaq deficiency notice on September 25, 2025, for failing to meet the minimum $15 million Market Value of Publicly Held Shares (MVPHS) requirement.
• The company's MVPHS has been below the $15 million threshold for 30 consecutive business days, indicating a potential risk to its Nasdaq listing.

Risks

• Failure to regain compliance with Nasdaq's $15 million MVPHS requirement by March 24, 2026, could lead to delisting.
• Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known, and could cause actual results to differ materially from those expressed or implied.
• Risks and uncertainties described in the Risk Factors section of the latest annual report on Form 10-K and the registration statement relating to the Transactions could materially impact future events and results.
• There may be additional risks that are currently unknown or believed to be immaterial that could also cause actual results to differ from forward-looking statements.

Future Outlook

Expectations relate to the terms and timing of the Transactions, future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of the Company, market size and growth opportunities, competitive position and technological and market trends, estimated implied pro forma enterprise value of the combined company, and the cash position of the combined company following the closing of the Transactions. The ability of SPAC and the Company to consummate the Transactions is also a key forward-looking aspect.

Industry Context

This filing reflects the ongoing trend of Special Purpose Acquisition Companies (SPACs) pursuing de-SPAC transactions to bring private companies public. The private placement is a common financing mechanism to support such mergers. The Nasdaq deficiency notice highlights the inherent volatility and scrutiny faced by SPACs, particularly concerning market capitalization and liquidity requirements, which can be a challenge for smaller or newly public entities in a competitive market.

Legal Proceedings

• Nasdaq Listing Qualifications Department issued a deficiency letter on September 25, 2025, for non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement (Nasdaq Listing Rule 5450(b)(2)(C)).

Stakeholder Impact

• Shareholders face potential delisting risk if Nasdaq compliance is not regained. The private placement could lead to minor dilution but also provides capital for the business combination. The ongoing business combination offers future growth potential.
• Investors in the private placement have their investment contingent on the business combination closing and subject to a six-month lock-up period. They also face the risk of potential delisting.

Next Steps

• Regain compliance with Nasdaq's $15 million MVPHS requirement by March 24, 2026.
• Consummate the SPAC Merger and Acquisition Merger as part of the business combination.
• PubCo to file a registration statement for the resale of the private placement shares within 60 calendar days after the Closing Date.
• PubCo to use commercially reasonable efforts to have the registration statement declared effective as soon as practicable, but no later than the 10th Business Day after SEC notification of no further review.

Key Dates

Recommendation

The company is at a critical juncture, balancing a strategic business combination with a significant regulatory challenge. While the private placement provides necessary capital for the merger, the Nasdaq deficiency notice introduces substantial uncertainty and risk to the company's listing status. Investors should hold, awaiting clarity on the resolution of the Nasdaq compliance issue and the successful completion of the business combination, as these factors will heavily influence future valuation.

Keywords

DT Cloud Acquisition Corporation, Maius Pharmaceutical, SPAC, Business Combination, Private Placement, Nasdaq Listing, Delisting Notice, MVPHS, Merger, Pharmaceutical Industry, Equity Financing